A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease
Status:
RECRUITING
Trial end date:
2027-09-14
Target enrollment:
Participant gender:
Summary
The primary efficacy objective of the trial is to assess the ability of TEV-53408 to attenuate gluten-induced enteropathy in adults with celiac disease.
The primary safety objective of the trial is to assess the safety of TEV-53408 in adults with celiac disease.
A secondary objective is to further assess the efficacy of TEV-53408 in adults with celiac disease.
The expected trial duration per participant is approximately 86 weeks.